Neurology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Figures Only
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow CME: Take the course for this article:
 Volume 68, Number 21, May 22, 2007
Right arrow Correspondence:
Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when Correspondence are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Kaloshi, G.
Right arrow Articles by Hoang-Xuan, K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kaloshi, G.
Right arrow Articles by Hoang-Xuan, K.
Related Collections
Right arrow Primary brain tumor
Right arrow Chemotherapy-tumor
Right arrow Clinical trials Observational study (Cohort, Case control)
Right arrow All Genetics
Right arrow Chromosomes
NEUROLOGY 2007;68:1831-1836
© 2007 American Academy of Neurology

Temozolomide for low-grade gliomas

Predictive impact of 1p/19q loss on response and outcome

G. Kaloshi, MD, A. Benouaich-Amiel, MD, F. Diakite, MD, S. Taillibert, MD, J. Lejeune, MSc, F. Laigle-Donadey, MD, M.-A Renard, MSc, W. Iraqi, MSc, A. Idbaih, MD, S. Paris, MSc, L. Capelle, MD, H. Duffau, MD, PhD, P. Cornu, MD, J.-M Simon, MD, K. Mokhtari, MD, M. Polivka, MD, A. Omuro, MD, A. Carpentier, MD, PhD, M. Sanson, MD, PhD, J.-Y Delattre, MD and K. Hoang-Xuan, MD, PhD

From APHP, Service de Neurologie Mazarin (G.K., A.B.-A., F.D., S.T., J.L., F.L.-D., M.-A.R., W.I., A.I., A.O., A.C., M.S., J.-Y.D., K.H.-X.), APHP, Service de Neurochirurgie (L.C., H.D., P.C.), APHP, Service de Radiothérapie (J.-M.S.), and APHP, Service de Neuropathologie (K.M.), Groupe hospitalier Pitié-Salpêtrière, Paris; INSERM U711 (A.I., S.P., A.C., M.S., J.-Y.D., K.H.-X.), Université Pierre et Marie Curie-Paris; Laboratoire Biologie des Interactions Neurone-Glie, Groupe hospitalier Pitié-Salpêtrière, Paris (A.I., S.P., A.C., M.S., J.-Y.D., K.H.-X); and APHP, Service d'Anatomopathologie (M.P.), Hôpital Lariboisière, Paris, France.

Address correspondence and reprint requests to Dr. K. Hoang-Xuan, Service de Neurologie Mazarin, Groupe Hospitalier Pitié-Salpêtrière, 47 Bd de l'Hôpital, 75651, Paris Cedex 13, France khe.hoang-xuan{at}psl.aphp.fr

Objective: To evaluate the predictive impact of chromosome 1p/19q deletions on the response and outcome of progressive low-grade gliomas (LGG) treated with up-front temozolomide (TMZ) chemotherapy.

Methods: Adult patients with measurable, progressive LGG (WHO grade II) treated with TMZ delivered at the conventional schedule (200 mg/m2/day for 5 consecutive days, repeated every 28 days) were retrospectively evaluated for response by central review of MRI-s. Chromosome 1p and 19q deletions were detected by the loss of the heterozygosity technique (LOH).

Results: A total of 149 consecutive patients were included in this retrospective, single center observational study. The median number of TMZ cycles delivered was 14 (range 2 to 30). Seventy-seven patients (53%) experienced an objective response (including 22 [15%] cases of partial response and 55 [38%] cases of minor response), 55 (37%) patients had stable disease, and 14 (10%) had a progressive disease. The median time to maximum tumor response was 12 months (range 3 to 30 months). The median progression-free survival (PFS) was 28 months (95% CI: 23.4 to 32.6). Material for genotyping was available for 86 patients. Combined 1p/19q LOH was present in 42% of the cases and was significantly associated with a higher rate (p = 0.02) and longer objective response to chemotherapy (p = 0.017), and both longer PFS (p = 4.10–5) and overall survival (p = 0.04).

Conclusion: Low-grade gliomas respond to temozolomide and loss of chromosome 1p/19q predicts both a durable chemosensitivity and a favorable outcome.

Received October 4, 2006. Accepted in final form February 7, 2007.




This article has been cited by other articles:


Home page
 Clin. Cancer Res.Home page
S. Kesari, D. Schiff, J. Drappatz, D. LaFrankie, L. Doherty, E. A. Macklin, A. Muzikansky, S. Santagata, K. L. Ligon, A. D. Norden, et al.
Phase II Study of Protracted Daily Temozolomide for Low-Grade Gliomas in Adults
Clin. Cancer Res., January 1, 2009; 15(1): 330 - 337.
[Abstract] [Full Text] [PDF]

Home page
 NeurologyHome page
W. P. Mason and J. G. Cairncross
Invited Article: The expanding impact of molecular biology on the diagnosis and treatment of gliomas
Neurology, July 29, 2008; 71(5): 365 - 373.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
B. Hegedus, D. Banerjee, T.-H. Yeh, S. Rothermich, A. Perry, J. B. Rubin, J. R. Garbow, and D. H. Gutmann
Preclinical Cancer Therapy in a Mouse Model of Neurofibromatosis-1 Optic Glioma
Cancer Res., March 1, 2008; 68(5): 1520 - 1528.
[Abstract] [Full Text] [PDF]

Home page
 NeurologyHome page
P. Y. Wen and L. M. DeAngelis
Chemotherapy for low-grade gliomas: Emerging consensus on its benefits
Neurology, May 22, 2007; 68(21): 1762 - 1763.
[Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2007 by AAN Enterprises, Inc.